Application of cannabidiol derivative in preparation of medicine for treating opioid drug addiction

By using the cannabidiol derivative formula I, the problems of addictiveness and withdrawal response in existing opioid addiction treatment methods have been solved, and effective treatment of opioid addiction, especially morphine addiction, has been achieved. And there are no addictive or side effects, ensuring the safety and effectiveness of treatment.

CN118986973APending Publication Date: 2024-11-22CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY CHINESE ACADEMY OF SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310569199.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-19
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing treatments for opioid addiction cannot effectively treat opioid addiction, especially morphine addiction, which has problems such as addictiveness and withdrawal reactions, and is ineffective on psychological dependence.

Method used

Using cannabidiol derivatives, specific compound formula I, is prepared by referring to the preparation method in CN112898190A, and is used to treat opioid addiction, which can inhibit withdrawal reactions and psychological dependence of physical dependence, and is not addictive. Low dose and stable effect.

Benefits of technology

Effectively treat opioid addiction, especially morphine addiction, inhibit withdrawal reactions, behavioral sensitization and conditional position preference, and has no addictiveness, side effects and acute toxicity, achieving better treatment safety and effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004237795780000021
    Figure BDA0004237795780000021
  • Figure BDA0004237795780000041
    Figure BDA0004237795780000041
  • Figure FDA0004237795770000011
    Figure FDA0004237795770000011
Patent Text Reader

Abstract

The invention provides an application of a cannabidiol derivative in preparation of a medicine for treating opioid drug addiction, and the cannabidiol derivative can achieve a very good treatment effect (very good treatment effects on withdrawal reaction, behavior sensitization and condition position preference). The traditional Chinese medicine composition is free of addiction, does not restrain breathing or damage short-term memory, does not have side effects or acute toxicity, and can achieve relatively good treatment safety.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to the use of a cannabidiol derivative in the preparation of a medicine for treating opioid addiction. Background Art

[0002] Opioids are psychoactive substances derived from the poppy or synthetic substances with similar effects, such as morphine and heroin. According to the World Health Organization, 69,000 people die from opioid overdoses each year worldwide. An estimated 15 million people are dependent on opioids (i.e., addicted to opioids).

[0003] Traditional treatments for opioid or morphine addiction are divided into:

[0004] 1. Drug maintenance treatment: Use weak opioid receptor agonists such as methadone, buprenorphine, opium tincture to replace morphine, a strong opioid receptor agonist, so as to continuously reduce the dosage and achieve the effect of drug detoxification. Disadvantages: These drugs themselves are also addictive.

[0005] 2. Treatment of withdrawal reaction: There will be strong withdrawal reaction during the treatment process. Generally, clonidine treatment (α2 agonist) can effectively suppress symptoms such as vomiting, diarrhea, increased blood pressure, and accelerated breathing; but it has poor effect on other symptoms (anxiety, insomnia). Scopolamine comprehensive drug detoxification method (M blocking drug): antagonizes the vagus nerve; controls the withdrawal symptoms of morphine addiction, reduces or reverses morphine tolerance, and promotes drug excretion. Disadvantages: This drug can only suppress the physical dependence caused by morphine, that is, withdrawal reaction, but has no effect on psychological dependence.

[0006] 3. Physical therapy: Exercise, acupuncture and other physical means are used to treat addiction, but the effects are limited.

[0007] Therefore, none of the above approaches are effective in treating opioid addiction. Summary of the invention

[0008] In view of this, the present invention provides an application of a cannabidiol derivative in the preparation of a drug for treating opioid addiction. The present invention uses a certain cannabidiol derivative as a drug for treating opioid addiction, which can effectively treat opioid addiction and has high safety.

[0009] The present invention provides an application of a cannabidiol derivative in the preparation of a drug for treating opioid addiction, wherein the cannabidiol derivative has a structure as shown in Formula I:

[0010]

[0011] In the present invention, the above-mentioned compound of formula I can be prepared by referring to the preparation method disclosed in CN112898190A, and specifically by referring to the preparation method disclosed in Example 1 of CN112898190A. The present invention uses the compound of formula I for treating morphine addiction, which can not only inhibit the physical dependence caused by morphine, i.e., withdrawal reaction, but also treat the psychological dependence induced by morphine, and at the same time, it is not addictive, has a low dosage, and has a stable effect.

[0012] The present invention uses cannabidiol derivatives as drugs for treating opioid addiction, wherein the opioid preferably includes morphine, tetrahydrocannabidiol, cocaine or heroin. More preferably, it is morphine, that is, it is especially used for treating morphine addiction.

[0013] In the present invention, the symptoms (or behaviors) of opioid addiction include at least one of withdrawal reaction, behavioral sensitization and conditioned place preference. The compound of formula I of the present invention can treat the above symptoms of opioid addiction.

[0014] In the present invention, the drug dosage (injection dosage) of the cannabidiol derivative can be ≤0.2 mg / kg, specifically 0.002 mg / kg, 0.02 mg / kg, 0.2 mg / kg, and most preferably 0.2 mg / kg.

[0015] Traditional drugs for treating morphine addiction have the disadvantages of being addictive and inducing withdrawal reactions, while the present invention uses the compound of formula I to treat morphine addiction, which can achieve good therapeutic effects (good therapeutic effects on withdrawal reactions, behavioral sensitization and conditioned place preference), and it is non-addictive, does not inhibit breathing and damage short-term memory, has no side effects and acute toxicity, and can achieve good treatment safety. In addition, its minimum effective dose is small. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0017] Figure 1 This is a diagram showing the effect of the withdrawal reaction experiment in Example 1;

[0018] Figure 2 is a diagram showing the effect of the behavioral sensitization experiment in Example 1; wherein Figure 2 (a) is the experimental effect diagram from day 1 to day 7. Figure 2 (b) is the experimental effect diagram on the 15th day;

[0019] Figure 3 This is a diagram showing the effect of the conditional position preference experiment in Example 1;

[0020] Figure 4 This is a diagram showing the effect of the CIAC001 addiction exploration-conditional place preference experiment in Example 2;

[0021] Figure 5 This is a rendering of the respiratory rate experiment in Example 2;

[0022] Figure 6 This is a rendering of the Y-maze test in Example 2;

[0023] Figure 7 This is a test effect diagram of mobility in the open field experiment in Example 2;

[0024] Figure 8 This is a test effect diagram of scratching behavior in the open field experiment in Example 2;

[0025] Fig. 9 This is a test effect diagram of the body weight test experiment in Example 2. DETAILED DESCRIPTION

[0026] In order to further understand the present invention, preferred embodiments of the present invention are described below in conjunction with examples. However, it should be understood that these descriptions are only for further illustrating the features and advantages of the present invention, rather than limiting the claims of the present invention.

[0027] In the following examples, the compound of formula I of the present invention is represented by CIAC001.

[0028] Example 1

[0029] 1. Withdrawal reaction experiment

[0030] principle:

[0031] After becoming addicted to morphine, administering the drug naloxone to block μ-opioid receptors triggers withdrawal reactions, and in severe cases the mice will jump.

[0032] process:

[0033] Thirty male Balb / c mice weighing about 25 g were selected and randomly divided into four groups, namely Group 1, Group 2, Group 3, and Group 4 (Groups 1-3: 5 mice each; Group 4: 15 mice).

[0034] Group 1 served as a blank control group (ie, the Vehicle group) and was not injected with any drug.

[0035] The following experiments were performed on groups 2 to 4: Day 1: intraperitoneal injection of morphine (1 injection dose of 5 mg / kg); Day 2: intraperitoneal injection of morphine (1 injection dose of 20 mg / kg); Day 3: intraperitoneal injection of morphine (1 injection dose of 40 mg / kg); In the above days 1 to 3, injections were given 3 times a day. Day 4: 40 mg / kg of morphine was injected intraperitoneally at 8 am. Three hours later, normal saline (injection dose of 8 mL / kg), cannabidiol CBD (injection dose of 0.2 mg / kg), CIAC001 (the mice in group 4 were further divided into 3 groups, and the injection doses of each group were 0.002 mg / kg, 0.02 mg / kg, and 0.2 mg / kg, respectively) were injected intraperitoneally 30 minutes later with 10 mg / kg of naloxone.

[0036] The number of jumps of mice in each group within 15 minutes was counted, and the average value of the test results of each group of mice was taken as the test result of that group.

[0037] Test results see Figure 1 and Table 1.

[0038] Table 1: Withdrawal reaction test results

[0039]

[0040] Conclusion: Figure 1 It can be seen from the test results in Table 1 that compared with Groups 2 to 3, the number of jumps of mice in Group 4 was significantly reduced, among which CIAC001 at a dose of 0.2 mg / kg was able to reduce the number of jumps of mice to the greatest extent, proving that the compound of formula I of the present invention (i.e., CIAC001) can effectively inhibit withdrawal reactions, while the effect of CBD is not obvious.

[0041] 2. Behavioral sensitization experiment

[0042] Principle: Long-term and repeated use of morphine leads to increased activity in mice.

[0043] process:

[0044] Twenty-four male Balb / c mice weighing about 25 g were selected and randomly divided into four groups (6 mice in each group), which were respectively named Group 1, Group 2, Group 3, and Group 4.

[0045] Group 1 served as a blank control group (ie, the Vehicle group) and was not injected with any drug.

[0046] The following experiments were conducted in groups 2 to 4: Day 1-7: Normal saline (injection dose of 8 mL / kg), cannabidiol CBD (injection dose of 0.2 mg / kg), and CIAC001 (injection dose of 0.2 mg / kg) were injected into mice in groups 2, 3, and 4 every day, and 30 minutes later, morphine (injection dose of 10 mg / kg) was injected into mice in groups 2 to 4, and then placed in an open field to move, and the movement distance of the mice was recorded for 1 hour. The experiment and recording were continued for 7 days (i.e., groups 2 to 4 were Morphine group, Morphine+CBD group, and Morphine+CIAC001 group, respectively). Day 8-14: Stop drug administration. Day 15: Intraperitoneal injection of morphine (injection dose of 5 mg / kg) was injected into mice in groups 2 to 4, and then placed in an open field to move, and the movement distance of the mice was recorded for 1 hour.

[0047] in conclusion:

[0048] Test results see Figure 2 , Figure 2 is a diagram showing the effect of the behavioral sensitization experiment in Example 1, wherein Figure 2 (a) is the experimental effect diagram from day 1 to day 7. Figure 2 (b) is the experimental effect diagram on day 15. It can be seen that compared with group 2 (Morphine group), the action distance of group 3 (Morphine+CBD group) did not decrease or even increased, while the action distance of group 4 (Morphine+CIAC001 group) was significantly reduced, proving that the compound of formula I of the present invention (i.e., CIAC001) can effectively inhibit morphine-induced behavioral sensitization, while CBD has no effect.

[0049] 3. Conditioned location preference experiment

[0050] principle:

[0051] Through repeated training, morphine is associated with the black and white box, and the effect of morphine on the mice's preference for the black and white boxes is observed to determine whether the mice have become dependent on morphine.

[0052] process:

[0053] Eighteen male Balb / c mice weighing about 25 g were selected. On the first and second days, the mice were adapted to the black and white boxes. On the third day, the mice were allowed to move freely between the black and white boxes to test their natural preference for the black and white boxes.

[0054] Training on days 4-9: The mice were randomly divided into 3 groups (6 mice in each group), respectively recorded as group 1, group 2 and group 3, among which group 1 was used as the blank control group (i.e., vehicle group) and no drug was injected. On days 4, 6, and 8, mice in groups 2 and 3 were injected with saline (injection dose of 8 mL / kg) and CIAC001 (injection dose of 0.2 mg / kg), respectively. 30 minutes later, mice in groups 2 and 3 were intraperitoneally injected with morphine (injection dose of 7.5 mg / kg) and placed in a non-natural preference box for 30 minutes. On days 5, 7, and 9, mice in groups 2 and 3 were injected with saline (injection dose of 8 mL / kg) and CIAC001 (injection dose of 0.2 mg / kg), respectively. 30 minutes later, mice in groups 2 and 3 were intraperitoneally injected with saline (injection dose of 7.5 mg / kg) and placed in a natural preference box for 30 minutes. Day 9: Allow the mice to move freely between the black and white boxes, and test their preference for the black box and the white box again. A change in preference indicates morphine addiction.

[0055] in conclusion:

[0056] Test results see Figure 3 It can be seen that compared with Group 1 (Vehicle group), the preference of Group 2 (Morphine group) changed, while the preference of Group 3 (Morphine+CIAC001 group) did not change, proving that the compound of formula I of the present invention (i.e., CIAC001) can inhibit morphine addiction.

[0057] The above-mentioned withdrawal reaction, behavioral sensitization experiment and conditioned place preference experiment are classic experiments for morphine addiction. The results of the above three experiments prove that the compound of formula I of the present invention (i.e., CIAC001) has a good therapeutic effect on the three experiments, indicating that it has a good effect in treating morphine addiction.

[0058] Example 2

[0059] 1. CIAC001 Addiction Research-Conditioned Place Preference Experiment

[0060] Principle: Through repeated training, CIAC001 is associated with the black and white boxes, and the effect of CIAC001 on the mice's preference for the black and white boxes is observed to determine whether the mice become dependent on CIAC001.

[0061] process:

[0062] Twelve Balb / c male mice weighing about 25 g were selected. On the 1st and 2nd days, the mice were adapted to the black and white boxes. On the 3rd day, the mice were allowed to move freely between the black and white boxes to test their natural preference for the black box and the white box.

[0063] Training on days 4-9: The mice were randomly divided into 2 groups (6 in each group), respectively recorded as Group 1 and Group 2, where Group 1 served as the blank control group (i.e., Vehicle group) and was not injected with any drug. On days 4, 6, and 8, CIAC001 (injection dose of 0.2 mg / kg) was given to mice in Group 2 and placed in a non-natural preference box for 30 min. On days 5, 7, and 9, mice in Group 2 were injected with saline (injection dose of 8 mL / kg) and placed in a natural preference box for 30 min. Day 9: The mice were allowed to shuttle freely between the black and white boxes, and their preference for the black box and the white box was tested again. Changes in preference indicated addiction to CIAC001.

[0064] in conclusion:

[0065] Test results see Figure 4 It can be seen that the compound of formula I of the present invention (i.e., CIAC001) does not change the preference of mice for the black and white boxes, indicating that it has low addictiveness.

[0066] 2. The influence of breathing rate and short-term memory

[0067] principle:

[0068] Cannabinoid compounds, especially tetrahydrocannabidiol (THC), inhibit breathing and impair short-term memory. The heart rate of mice was tested 30 minutes after administration using a small animal monitor. The short-term memory of mice was tested using a Y-maze. Normal mice would recognize new passages and stay next to new objects in the new passages, but after memory impairment, they could not recognize new objects.

[0069] process:

[0070] Eighteen Balb / c male mice weighing about 25 g were selected and randomly divided into three groups (6 mice in each group), respectively recorded as Group 1, Group 2 and Group 3, among which Group 1 was used as a blank control group (i.e., Vehicle group) and was not injected with any drug. Days 1-5: THC (injection dose of 10 mg / kg) and CIAC001 (injection dose of 20 mg / kg) were injected intraperitoneally to mice in Group 2 and Group 3, respectively. On the second and fifth days, the respiratory rate changes of mice were monitored using a small animal monitor 30 minutes after the injection. Day 3: THC (injection dose of 10 mg / kg) and CIAC001 (injection dose of 20 mg / kg) were injected intraperitoneally to mice in Group 2 and Group 3, respectively. 30 minutes after the injection, the channel on the new object side of the Y maze was blocked, and mice from groups 1 to 3 were allowed to explore the Y maze for 5 minutes. Then, after the mice were placed in the cage for 2 minutes, the channel on the new object side of the Y maze was opened, and mice from groups 1 to 3 were allowed to explore freely for 2 minutes. The time the mice spent on the new object side and the old object side was counted. Conclusion:

[0071] The results of the respiratory rate test can be found in Figure 5It can be seen that after intraperitoneal injection of THC, the respiratory rate of group 2 decreased compared with group 1 (Vehicle group), while after intraperitoneal injection of CIAC001 in group 3, its respiratory rate did not change significantly, indicating that CIAC001 does not inhibit the respiration of mice. Figure 6 It can be seen that after intraperitoneal injection of THC, the time spent on the new object side in Group 2 was significantly reduced compared with Group 1 (Vehicle group), while after intraperitoneal injection of CIAC001 in Group 3, the time spent on the new object side did not change significantly. The above experimental results prove that intraperitoneal injection of THC will inhibit breathing and damage short-term memory, while injection of the compound of formula I of the present invention (i.e. CIAC001) will not cause this situation, and will not inhibit breathing and damage short-term memory.

[0072] 3. Open field test: mobility and scratching behavior

[0073] principle:

[0074] If the drug has side effects that cause the mice to feel uncomfortable and anxious, it will cause the mice to walk longer distances in the open field and scratch themselves.

[0075] process:

[0076] Seven male Balb / c mice weighing about 25g were selected and placed in an open field for 1 hour before the experiment. Their behaviors (including walking distance and number of scratching) were recorded, and the average value was taken as the test result of this group of mice (this test result is Pre-Test). Then, CIAC001 (injection dose of 20mg / kg) was injected intraperitoneally into the mice for 7 consecutive days. On the 8th day, the mice were placed in an open field again for 1 hour, and their behaviors (including walking distance and number of scratching) were recorded. The average value was also taken as the test result of this group of mice (this test result is Test).

[0077] in conclusion:

[0078] The test results of walking distance and scratching times are shown in Figure 7 and Figure 8 It can be seen that compared with the Pre-Test, there was no significant change in the walking distance and the number of scratching times of the Test group, that is, there was no obvious anxiety behavior after administration of the compound of formula I of the present invention (i.e., CIAC001), proving that the compound of formula I of the present invention has no side effects.

[0079] 4. Weight test

[0080] Principle: If the drug is acutely toxic, it will cause mice to lose weight.

[0081] process:

[0082] Thirty-six male Balb / c mice weighing about 25 g were selected and randomly divided into two groups (18 mice in each group), respectively recorded as Group 1 and Group 2. Group 1 was used as a blank control group (i.e., Vehicle group) and was not injected with any drug. Group 2 mice were intraperitoneally injected with CIAC001 (injection dose of 20 mg / kg) for 7 consecutive days. The weight changes of mice in each group were recorded every day, and the average value of mice in each group was taken as the test result of the mice in that group.

[0083] in conclusion:

[0084] Test results see Fig. 9 It can be seen that compared with Group 1 (Vehicle group), the body weight of Group 2 (CIAC001 group) was basically unchanged, that is, the compound of formula I of the present invention (i.e., CIAC001) had no effect on the body weight of mice, proving that the compound of formula I of the present invention has no acute toxicity.

[0085] The above experiments prove that the compound of formula I of the present invention does not inhibit breathing and damage short-term memory, does not produce side effects, and has no acute toxicity. In general, compared with THC, CIAC001 is a synthetic substance with no addictiveness and few side effects, and is safer when used to treat morphine addiction.

[0086] In summary, the present invention uses the compound of formula I for the treatment of morphine addiction, which can achieve good therapeutic effects (it has good therapeutic effects on withdrawal reactions, behavioral sensitization and conditioned place preference), and it itself is non-addictive, has no side effects and acute toxicity, and can achieve good therapeutic safety.

[0087] Specific examples are used herein to illustrate the principles and implementation methods of the present invention. The description of the above embodiments is only used to help understand the method of the present invention and its core ideas, including the best mode, and also enable any technician in the field to practice the present invention, including making and using any device or system, and implementing any combined method. It should be pointed out that for ordinary technicians in this technical field, without departing from the principle of the present invention, the present invention can also be improved and modified, and these improvements and modifications also fall within the scope of protection of the claims of the present invention. The scope of patent protection of the present invention is defined by the claims and may include other embodiments that can be thought of by those skilled in the art. If these other embodiments have structural elements similar to the literal expression of the claims, or if they include equivalent structural elements that are not substantially different from the literal expression of the claims, then these other embodiments should also be included in the scope of the claims.

Claims

1. The use of cannabidiol derivatives in the preparation of a drug for treating opioid addiction, characterized in that: The cannabidiol derivative has a structure shown in Formula I:

2. The use according to claim 1, characterized in that: The opioids include morphine, tetrahydrocannabidiol, cocaine or heroin.

3. The use according to claim 1, characterized in that: The symptoms of opioid addiction include at least one of withdrawal reactions, behavioral sensitization, and conditioned place preference.